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Introduction
Periodontitis is initiated by microbial biofilms, which in turn 
elicit a host response and result in the destruction of the peri-
odontal tissue (Van Dyke and Serhan 2003). Uncontrolled 
inflammation and failed resolution of the inflammation are con-
sidered the underlying mechanism of periodontitis (Van Dyke 
and Serhan 2003; Serhan et al. 2007; Medzhitov 2010; Serhan 
2010). In literature, robust evidence has shown that an endoge-
nous anti-inflammatory and proresolving process can depress 
chronic inflammation and activate wound healing with tissue 
regeneration (Serhan et al. 2007; Serhan et al. 2008; Ortega-
Gómez et al. 2013). This active process is orchestrated, in part, 
by specialized endogenous proresolving lipid mediators 
(SPMs), including lipoxins, resolvins, protectins, and maresins 
(Levy et al. 2012; Kamaly et al. 2013; Ortega-Gómez et al. 
2013). SPMs can actively reduce neutrophil infiltration into 
inflamed tissues, enhance efferocytosis and bacterial phagocy-
tosis by monocytes and macrophages, and simultaneously 
inhibit inflammatory cytokine production (Lee et al. 2016).
Topical usage of resolvin E1 and lipoxin A4 (LXA4) has 
already been proven to prevent periodontal bone loss and acti-
vate the periodontal regeneration in rabbits and swine, without 
the multiple side effects ascribed to traditional anti-inflamma-
tory antagonist-based treatments (Hasturk et al. 2006; Hasturk 
et al. 2007; Van Dyke et al. 2015; Lee et al. 2016). We hypoth-
esize that topical application of SPMs without an appropriate 
carrier may not be able to achieve an effective retention in the 
periodontal pocket and a drug carrier system would be advan-
tageous. For instance, Van Dyke et al. (2015) delivered 
 membrane-shed vesicles incorporating LXA4 in swine, result-
ing in significant regeneration of bone and connective tissues 
and reestablishment of the periodontal organ. The commonly 
used carriers for sustained drug release include microspheres, 
polymer chips, fibers, and hydrogels (Joshi et al. 2016). Among 
all the carriers, thermoresponsive hydrogels are particularly 
attractive, because they are liquid at low temperature and thus 
can be easily injected into deep pockets, and then, they can 
form gels under body temperature to facilitate sustained drug 
release (Vyas et al. 2000; Maheshwari et al. 2006; Ji et al. 
2010; Nasra et al. 2017). The commercially available polox-
amer 407 (P407) has been studied for this purpose. P407 
exhibits a thermoresponsive manner at a concentration above 
20% w/w, but it is easy to be eroded after gelation under the 
influence of surrounding liquid (Zhang et al. 2002). Recently, 
another thermoresponsive hydrogel based on polyisocyano-
peptide (PIC) has been developed, which can form a gel at 
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Abstract
The objective of this study was to evaluate a novel thermoresponsive polyisocyanopeptide (PIC)–based hydrogel as an injectable 
carrier for local drug delivery for periodontal applications. Three formulations of PIC gels, 0.2%, 0.5%, and 1% w/w, were prepared. As 
controls, commercially available poloxamer 407 (P407) gels of 20% and 26% w/w were used. Lipoxin A4 (LXA4), a proresolving drug, 
was suspended into the gel solutions. The systems were evaluated regarding dynamic mechanical properties, injectability and stability, 
release and bioactivity of LXA4, and cytocompatibility. Results showed that the gelation temperatures of PIC and P407 gels were around 
13°C to 23°C. PIC gels were less viscous and mechanically weaker than P407 gels due to the low polymer concentrations. However, 
PIC gels kept gel integrity for at least 2 wk when incubated with phosphate-buffered saline, whereas P407 gels were disintegrated totally 
within 1 wk. LXA4 was chemically stable in both neutral and alkaline medium for over 1 mo. The release of LXA4 from either 1% PIC or 
26% P407 gels depicted an initial burst release followed by a sustained release for around 4 d. The extent of burst release was negatively 
correlated to the polymer concentration. LXA4 remained bioactive after release from PIC gels. No cytotoxicity was observed for 1% 
PIC gel. However, 26% P407 inhibited periodontal ligament cell and gingival epithelial cell growth. In conclusion, the thermoresponsive 
PIC gel is a potential candidate for periodontal drug delivery.
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extremely low polymer concentrations (~0.5%) and displays 
strain-stiffening properties comparable to the natural extracel-
lular matrix (Kouwer et al. 2013; Das et al. 2016). This gel 
system may have the advantages of 1) low viscosity, allowing 
the drug solution to perfuse periodontal pockets fully, and 2) 
low toxicity induced by the polymers.
This study aimed at evaluating the thermoresponsive PIC 
hydrogel loaded with LXA4 as a representative SPM for the 
periodontal application. To this end, 0.2% to 1% w/w PICs were 
prepared. Then, the physical stability and dynamic mechanical 
properties of the gels were tested, in comparison with 20% and 
26% w/w P407 controls. LXA4 release profiles from PICs or 
P407s were further investigated. The efficacy of the released 
LXA4 was tested by a phagocytic test. Finally, the cytocompat-
ibility of the gel systems was tested using periodontal ligament 
cells (PDLCs) and gingival epithelial cells (GECs).
Materials and Methods
Preparation of Thermoresponsive Gels
PIC polymer (molecular weight ~ 635 kDa) was provided by 
Dr. Paul H. J. Kouwer (Institute for Molecules and Materials, 
Radboud University, the Netherlands). PIC or P407 (Sigma-
Aldrich) polymer was dissolved in cold phosphate-buffered 
saline (PBS). Three PIC solutions at 0.2, 0.5, and 1% w/w and 
2 P407 solutions at 20% and 26% w/w were prepared. The pH 
of the prepared solutions was determined at 4°C.
Physical Characterization of the Gels
Dynamic mechanical properties of gels were tested by a rhe-
ometer with a temperature sweep program (see Appendix for 
method). The sol-gel transition temperature (Tsol-gel) was deter-
mined as the crossing point of storage (G′) and loss (G′′) mod-
uli during temperature sweep measurements. The values of G′ 
and G′′ of each gel at 37°C were recorded after a 2-min equili-
bration. Injectability of gels was tested with Milli-Q water as a 
control (see Appendix for method).
Physical stability of hydrogels, in an aqueous solution, was 
tested by a gravimetric method (Zhang et al. 2002). Briefly, 
0.5 mg gel solution was injected into the bottom of an 
Eppendorf tube with a known weight (W0/mg) and gelled at 
37°C. Three aqueous buffers at different pH were prepared: 1) 
PBS (pH 7.4), 2) 4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid (HEPES; pH 8.5), and 3) citrate acid (pH 5). All 
buffers had an ionic strength of 154 mM. Afterward, 1 mL buf-
fer was carefully laid over the surface of the gel. All samples 
were incubated at 37°C with gentle agitation at 120 rpm/min. 
At each predetermined time point, all the supernatant was care-
fully removed, and the Eppendorf tubes were weighted again 
(Wt/mg). Then, 1 mL fresh buffer was refilled, and samples 
were incubated until the next time point. The erosion profiles 
were obtained by plotting the percentage remaining for each 
gel formulation ([Wt – W0]/0.5 × 100%) against the incubation 
time (n = 3).
In Vitro Release of LXA4
To detect the stability of LXA4 in aqueous solutions, 100 µg/mL 
15(R)-LXA4 in ethanol (Cayman Chemical) was diluted to 
1 µg/mL using the 3 above aqueous buffers at different pH. 
After dilution, the samples (n = 3) were incubated at 37°C and 
the amount of LXA4 in the buffers at predetermined time points 
was detected by reverse-phase high-performance liquid chro-
matography (RP-HPLC; Hitachi) (for details, see Appendix).
Release studies were performed at 37°C by a membraneless 
dissolution method (Zhang et al. 2002). Briefly, 200 µL of a 
PIC or P407 solution was mixed with 1 µg LXA4 on ice and 
then gelled in an Eppendorf at 37°C (n = 4). Subsequently, 1 
mL PBS prewarmed at 37°C was laid over the gels. Samples 
were then incubated at 37°C with agitation at 200 rpm/min. At 
each predetermined time point, 900 µL supernatant was with-
drawn carefully and 900 µL fresh PBS was refilled. The amount 
of released LXA4 in the supernatant was detected by RP-HPLC.
To further investigate the interactions between LXA4 and 
hydrogel carriers and influential factors of LXA4 release, the 
release study was also performed in media with detergent of 
0.1% v/v Tween 20 in PBS (n = 4) and in buffers with different 
pH (n = 4): 1) PBS (pH 7.4), 2) HEPES (pH 8.5), and 3) citrate 
acid (pH 5) (Song et al. 2015).
In Vitro Efficacy Test
The efficacy of the released LXA4 was assessed by the ability 
to stimulate macrophage phagocytosis. The phagocytic activity 
of RAW264.7 macrophages was examined using a fluorescent 
bead internalization assay (Prescott and McKay 2011). Cells 
were seeded in 96-well plates at a density of 2 × 104 cells/cm2 
in α–minimum essential medium eagle containing 1%  penicillin- 
streptomycin (P/S) and 10% fetal bovine serum (FBS) and left 
for 24 h for attachment prior to experimentation. Thereafter, 
each macrophage was exposed to 100 latex beads labeled with 
Nile red fluorescence (D = 2 µm; Invitrogen). Then, 50 µL 
LXA4 releasate from gels (concentration calculated by HPLC 
results) or freshly prepared LXA4 (positive control) was added 
into the culture to reach a final LXA4 concentration of 100 nM. 
The same volume of ethanol, the drug vehicle, was used as a 
negative control. After incubation for 4 h, the fluorescence of 
unphagocytic beads was quenched with 0.4% trypan blue. The 
fluorescence intensity of each well was read in a Synergy HTX 
multimode reader (BioTek Instruments), with the excitation/
emission wavelength at 535/575 nm. The wells without beads 
were assessed to determine background fluorescence. Data 
were expressed as a percent change in fluorescence in treated 
versus control wells. Phagocytosis results were also visualized 
by fluorescent microscopy (see Appendix for method).
In Vitro Cytocompatibility Test
Cytocompatibility of LXA4/PIC and LXA4/P407 was tested 
using human PDLCs and GECs. Cells were harvested from 
extracted third molars with the informed consent of the patients 
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(all ~20 y old). Cell culture methods are shown in the Appendix. 
PDLCs or GECs were seeded on 24-well plates or Thermanox 
coverslips at a density of 1 × 104 cells/cm2 for 24 h before the 
assays.
Then, 200 µL cold gel solution with or without LXA4 was 
injected in Corning Transwell cell culture inserts (pore size = 
8 µm) and gelled at 37°C. Next, the transwells were inserted sepa-
rately into the wells with PDLCs or GECs. The final concentra-
tion of LXA4 for the LXA4-loaded groups was 100 nM calculated 
according to the whole liquid volume in each well. The cytocom-
patibility of gels was tested by alamarBlue, DNA assay, and live/
dead staining at days 2 and 4 (see Appendix for methods).
Statistical Analysis
All data were reported as a mean ± standard deviation and ana-
lyzed using 1-way analysis of variance by GraphPad Prism 7.0 
(GraphPad Software). Differences were considered statisti-
cally significant at P < 0.05.
Results
Physical Characterization of the Gels
As shown in the Table, the pH of all gel groups was 7.4 and 
same with PBS. Tsol-gel of all formulations was between 13°C 
and 23°C. With the increase of PIC or P407 concentration, Tsol-
gel slightly dropped, whereas, G′ and G′′ increased. Both G′ and 
G′′ of PICs were lower than those of P407s. Overall, PIC solu-
tions were less viscous than P407 solutions. All the ice-chilled 
solutions were easily pushed through a 22-gauge needle com-
parable to water (Appendix Fig. 1).
All PIC and P407 gels stayed at the bottom of the Eppendorf 
without detachment. Regardless of buffers, P407, 20% and 26% 
w/w, disintegrated completely within 5 and 7 d, respectively 
(Fig. 1). In contrast, even the weakest 0.2% PIC remained ~70% 
after 15 d. As expected, the rate of gel disintegration decreased 
as the concentration of gel increased. There was almost no 
weight loss for 1% PIC gel up to 15 d. pH did not show any sig-
nificant influence on gel integrity for both PIC and P407.
In Vitro Release of LXA4
Chemical stability of LXA4 results (Fig. 2A) revealed that over 
80% of LXA4 remained intact in 1 wk under various pH 
conditions. After 1 mo, LXA4 was relatively stable in neutral 
and alkaline solution but fully degraded in acidic buffer.
The release profile displayed a burst release of 40% to 60% 
LXA4 in the first 8 h (Fig. 2E–G) and a sustained release there-
after for around 4 d for all groups (Fig. 2B–G). Polymer con-
centration had a minor effect on the duration of LXA4 release 
but considerably decreased the initial burst release. The 26% 
P407 formulation possessed a similar release pattern to 1% 
Table. In Vitro Characterization of PIC or P407 Gels with Different Polymer Concentrations (n = 3): pH, Tsol-gel Sol-Gel Transition Temperature, and 
Storage (G′) and Loss (G′′) Moduli at 37°C.
Gel Concentration (w/w) pH Tsol-gel (°C), Mean ± SD G′ (Pa), Mean ± SD G′′ (Pa), Mean ± SD
PIC 0.2% 7.4 16.5 ± 0.8a 334 ± 62a 33 ± 3a
0.5% 7.4 16.2 ± 0.4a 1,050 ± 77a 45 ± 11a
1% 7.4 12.9 ± 1.0b 4,964 ± 353b 195 ± 42a
P407 20% 7.4 22.9 ± 0.4c 16,101 ± 289c 787 ± 121b
26% 7.4 18.2 ± 0.4a 28,422 ± 1,585d 859 ± 121b
Different superscript letters in each column indicate significant difference between different groups.
Figure 1. The erosion profile of polyisocyanopeptide (PIC) or 
poloxamer 407 (P407) gels with different polymer concentrations in 
phosphate-buffered saline (A), citrate buffer (B), and HEPES (C) at 
37°C versus time. Results are shown as the percentage of gel-remaining 
weight. Data are expressed as mean ± standard deviation (n = 3). The 
sign of standard deviation may not visible when it is smaller than the data 
symbol.
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PIC, but the gel dissolved fast during the release test. Finally, 
the cumulative release amounts reached more than 90% for 
PICs, in contrast to around 80% for the P407s.
The addition of Tween 20 signifi-
cantly increased the release rate of 
LXA4 with 90% of cumulative 
release within 1 d in PIC groups (Fig. 
2C). Especially, in the first 8 h, 
around 20% more LXA4 was released 
compared to that in the PBS. The 
LXA4 release in alkaline medium 
showed the same pattern as that in 
Tween 20. In acidic medium, the 
release rate was low, but in total, 
only around 70% of LXA4 was 
released. For P407 groups, the LXA4 
release was not greatly affected by 
detergent and alkaline medium in 
velocity, duration, and cumulative 
amount (Fig. 2D). Similarly, less 
LXA4 amount was finally released 
from the P407 in the acidic buffer.
In Vitro Efficacy and 
Cytocompatibility Test
Phagocytotic activity of RAW264.7 
is shown in Figure 3. Both LXA4 
released from PIC and fresh LXA4 
enhanced the phagocytosis activity 
of RAW264.7. However, no phago-
cytic enhancement was detected for 
the LXA4 released from P407 or in 
the groups without LXA4 (Fig. 3C). 
Phagocytic images illustrated that 
more fluorescent particles were 
internalized in PIC/LXA4 groups 
compared to PIC without LXA4 
groups (Fig. 3A and B).
Results of cytocompatibility test 
are shown in Figure 4. The response 
of PDLCs and GECs to different gel 
systems was similar. One percent 
PIC and PIC/LXA4 showed good 
cell viability, while 26% P407 and 
P407/LXA4 hindered cell growth, 
similar to 5% dimethyl sulfoxide 
(DMSO) (Fig. 4A and C). The DNA 
assay results corroborated that cells 
cultured with PICs had significantly 
higher amounts of DNA than those 
with P407s (Fig. 4B and D). The 
live/dead staining (Fig. 4E and F) 
displayed that most cells were via-
ble in PIC groups, and dead cells 
were seldom found. However, a considerable number of 
dead cells and less live cells could be seen in the P407 
groups.
Figure 2. Lipoxin A4 (LXA4) stability and release curves. (A) LXA4 chemical stability in media with 
different pH and (B–D) the cumulative release profiles of LXA4 from different gels with different 
release media. (A) Eighty percent of LXA4 remained intact after 1 wk under various pH conditions. 
After 1 mo, around 70% of LXA4 was left in the neutral solution and more than 90% in the alkaline 
buffer. However, no LXA4 could be detected in the acidic buffer. (B) LXA4 release from 0.2%, 0.5%, 
1% w/w polyisocyanopeptide (PIC) and 26% w/w poloxamer 407 (P407) gels in phosphate-buffered 
saline release medium at 37°C. (C) Detergent and pH influence of LXA4 release from 0.2% PIC gel. (D) 
Detergent and pH influence of LXA4 release from 26% P407 gel. The partial enlargement of release 
pattern of first 8 h in B, C, and D are shown in E, F, and G, respectively. The sign of standard deviation 
may not visible when it is smaller than the data symbol.
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Discussion
This study aimed to explore the feasibility of thermoresponsive 
PIC gel for controlled release of LXA4 and to evaluate their 
potential for clinical periodontal applications. Three important 
parameters were considered: 1) the placement and retention of 
the dosage form at the site of application, 2) the ability to offer 
controlled drug release, and 3) the cytocompatibility of the gel 
(Jones et al. 2009). P407 was adopted as the control (Bruschi 
et al. 2007; Kumari and Pathak 2012). The results revealed that 
PIC possessed good clinical potential featured by its conve-
nient handling ability and long-term stability, facilitating sus-
tained release of LXA4 and cytocompatibility.
When developing a topically applied drug, the first consid-
eration would be the local physiological conditions. The pH 
within the periodontal pocket was reported as ranging from 2 
to 9, depending on the physiological or pathological conditions 
(Galgut 2001). The stability results of LXA4 stated its integrity 
for at least 1 wk regardless of the pH. However, LXA4 quickly 
degraded or isomerized in 1 mo in the acidic solution, indicat-
ing that the drug formulation needs to be carefully designed if 
a longer treatment period in a low pH environment is desired.
To obtain a sustained release of the intended drug in the 
periodontal pockets, thermoresponsive gels have unique 
advantages to easily perfuse the deep or irregular pockets upon 
injection at low temperature and then form gel immediately to 
facilitate drug release in the pockets. The average pocket tem-
perature has been reported to be 36.6°C ± 0.4°C (Haffajee et al. 
1992). Both PIC and P407 gels had Tsol-gel between 13°C and 
23°C; thus, they can be easily injected through thin needles in 
a second and gel in situ, which contributes to their good han-
dling ability. The process of thermally induced PIC gel forma-
tion is attributed to hydrophobic effects caused by the ethylene 
glycol tails grafted onto its polyisocyanide backbone (Kouwer 
et al. 2013). For P407 gel, micellar desolvation and swelling 
give rise to a large cross-linked micelle network when the 
 temperature rises (Veyries et al. 1999). The PIC gels showed a 
much lower G′′ than P407, indicating a superior flowability to 
fully irrigate deep, irregular pockets. After injection, the long-
term retention of the gel in the pockets is the premise of a sus-
tained release. P407 gels disintegrated much faster than PIC 
gels. This result corroborates the previous report that the 
orderly packed micelles of P407 dissociated gradually with the 
influence of surrounding liquid (Dumortier et al. 2006). In con-
trast, PIC has a stiff helical polyisocyanide backbone stabilized 
with the hydrogen-bonded dialanyl groups, which enables PIC 
to form a semiflexible network in water and thus tolerate the 
microflow. However, this setting of the gel stability test in this 
study is not comparable to the in vivo complicated condition, 
for example, a) continuous epithelial turnover at the interface, 
b) flow of gingival crevicular fluid, c) efflux of immune cells, 
and d) gravity. Although PIC gel is not biodegradable, it can be 
removed by cold water irrigation. Several thermosensitive 
hydrogel products, mostly based on poloxamers, have been 
developed for periodontal application (Maheshwari et al. 2006; 
Pandit et al. 2016; Nasra et al. 2017). Poloxamers degrade very 
slowly (Erlandsson 2002) and preferably should be cleaned by 
cold rinsing. At the same time, such a procedure would also 
prevent the (unlikely) possibility that remaining gel would hin-
der the reattachment of periodontal tissue. To our knowledge, 
there have been no reports showing that periodontal gels pre-
vented the reattachment; instead, gels incorporated with thera-
peutic agents displayed a favorable effect on periodontal 
regeneration (Maheshwari et al. 2006; Nasra et al. 2017). After 
disintegration, PIC gels may enter the digestive tract before 
irrigation and may be excreted out of body with feces like PEG 
gel (Sternebring et al. 2016) or with urine, as shown in the 
other study of our group (unpublished data). Based on the 
results of stability and drug release in this study, PIC gel is sug-
gested to be changed in weekly cycles.
Besides handling ability and physical stability, a more 
important aspect is the release of the targeted drugs. Several 
aspects may affect the release of LXA4 from gels: the 
Figure 3. Lipoxin A4 (LXA4) released from polyisocyanopeptide (PIC)/LXA4 upregulated phagocytosis by RAW264.7 macrophages, as visualized 
by fluorescence microscopy and quantified. (A) RAW264.7 cells incubated with released medium from PIC gel without LXA4; (B) RAW264.7 cells 
incubated with 100 nM LXA4 released from PIC/LXA4 (nuclei were stained by 4’,6-diamidino-2-phenylindole (DAPI) to blue; actin was stained by 
phalloidin 568 to red; particles were yellow-green). (C) Differences of fluorescence in groups over naive control (n = 4, results are expressed as mean 
± SD, **P < 0.01, ***P < 0.001 compared with naive controls). In positive control (free LXA4), a 27.18% ± 3.2% increase in RAW264.7 phagocytosis; 
LXA4 released from PIC gel enhanced the phagocytosis activity by 23.75% ± 8.4%. No positive effect on phagocytosis could be found for the LXA4 
released from poloxamer 407 (P407). As expected, no enhancement of phagocytosis was found for the groups without LXA4 (1% PIC and 26% P407) 
as well.
6 Journal of Dental Research 00(0)
Figure 4. Cytocompatibility of 1% polyisocyanopeptides (PICs) and 26% poloxamer 407 (P407s) with or without lipoxin A4 (LXA4) on periodontal 
ligament cells (PDLCs) and gingival epithelial cells (GECs). (A) PDLC viability test on day 2 and day 4 by alamarBlue. PIC and PIC/LXA4 showed good 
cell viability comparable to the positive control, while P407 and P407/LXA4 had only around 36% cell viability at day 2 and 25% at day 4, same as 
5% dimethyl sulfoxide (DMSO). Cell viability is normalized by control group (cells cultured on cell culture plate without gel); the black dashed line 
represents the control group with 100% viability. (B) Total PDLC DNA content on day 2 and day 4. Cells cultured with PIC gels had significantly 
higher amounts of DNA than those with P407 gels. ****P < 0.0001. (C) GEC viability test on day 2 and day 4 by alamarBlue. PIC and PIC/LXA4 showed 
good viability on GECs comparable to that on PDLCs. P407 and P407/LXA4 were less toxic to GECs than to PDLCs, which is around 70% cell viability 
at day 2 and 50% at day 4. (D) Total GEC DNA content. In the PIC and PIC/LXA4 group, DNA content is comparable to control on days 2 and 4. A 
significantly lower DNA amount was shown for P407 and P407/LXA4 than that for the control group. Live/dead staining of PDLCs (E) and GECs (F) 
culturing with 1% PICs and 26% P407s with or without LXA4 of 2 d and 4 d. A few fibroblasts from the gingival tissues could also be found in GEC 
culture. Green, live cells; red, dead cells. Scale bar is 200 µm.
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solubility and diffusion rate of the drug, as well as the erosion 
of the gels. LXA4 theoretically possesses 3 hydroxyl residues, 
1 carboxyl residue, and 4 double bonds (Serhan et al. 1984), 
which facilitate binding to the polyisocyanide backbone and 
ethylene glycol tails of PIC by hydrogen bonds and hydropho-
bic interactions. It can be inferred that the higher the polymer 
concentration, the more hydrogen bonds are formed, resulting 
in a slower and prolonged release, as shown in this study. The 
addition of detergent significantly increased the release rate, 
which confirms the hydrophobic interaction (Song et al. 2015). 
For practical concerns, if enough surfactant in the dentifrices 
goes inside the pockets, it may accelerate LXA4 release. 
Similarly, LXA4 release accelerates when pH increases, possi-
bly because the carboxyl residues become more ionized in the 
base, which increases the drug solubility in water (Savjani 
et al. 2012). Correspondingly, the release rate was slower in 
acid probably due to decreased drug solubility. Regarding 
P407, LXA4 can be trapped inside of its micelles, which act as 
a barrier to weaken the effect of detergent and base (Dumortier 
et al. 2006). Because P407 is easily eroded, LXA4 release 
relied on the gel erosion besides diffusion (Zhang et al. 2002; 
Maheshwari et al. 2006). The LXA4 total release amount 
diminished in the acidic medium for both PIC and P407 likely 
due to the degradation induced by acid. Finally, it is mention-
able that a cumulative release amount reached around 90% in 
PICs and 80% in P407s. Not fully releasing may also partially 
be attributed to the slow degradation of LXA4.
A phagocytic activity test was used to evaluate the efficacy 
of LXA4 released from gels (Prescott and McKay 2011). Only 
LXA4 from PIC gels promoted phagocytosis of macrophages. 
Since there is no obvious chemical reaction between LXA4 and 
P407, it is highly unlikely that the presence of P407 leads to 
deactivation of LXA4. Therefore, other substances in the P407 
releasates may hinder the phagocytosis process, which coun-
teracts the LXA4 effect. Further cytocompatibility experimen-
tation revealed that P407 could be toxic to PDL and GEC cells, 
which could explain the low phagocytosis in the P407/LXA4 
group. In practice, w/w ≥20% P407 is widely used (e.g., for 
oral, rectal, ophthalmic usage) in vivo (Ji et al. 2010). Some 
studies reported that low concentrations of P407 had no inher-
ent cytotoxicity (Hokett et al. 2000; Exner et al. 2005), but the 
cytotoxicity at 20% or higher concentration has not been 
reported yet. Based on our study, 26% P407 has unexpected 
growth inhibition to PDL cells in transwell culture, which may 
be due to its easy dissolution to the medium through the tran-
swell pores. Such hindrance of cell growth should be further 
investigated. In contrast to P407, PIC did not erode to such an 
extent but remained more stable and cytocompatible. Because 
metabolic assays (e.g., alamarBlue) could not accurately reflect 
cellular proliferation rates, a discrepancy was observed 
between the viability and proliferation results in PIC groups 
and the control group (Fig. 4A and B) (Quent et al. 2010). A 
recent study demonstrated that fibroblasts, endothelial cells, 
adipose-derived stem cells, and melanoma cells did survive, 
thrive, and differentiate in PIC gels, further confirming its cyt-
ocompatibility (Zimoch et al. 2018).
Conclusion
In this study, PIC/LXA4 gel featured by convenient handling 
ability was stable for over 2 wk. It was capable of releasing 
LXA4 in a sustained manner while preserving biological activ-
ity and was cytocompatible. In conclusion, PIC hydrogel was 
appropriate for the intended periodontal applications, and its 
clinical potential for treating periodontitis should be further 
developed.
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